1. A 27-year-old primigravida delivers vaginally after an uncomplicated labor. Her blood pressure was 132/86 mmHg on admission but was not repeated in the final 45 minutes of the second stage. Immediately after placental delivery, the obstetrician administers methylergonovine 0.2 mg IM for routine PPH prophylaxis. Seven minutes later the patient reports a severe throbbing headache. Vital signs reveal blood pressure 182/116 mmHg, heart rate 94 bpm. The nurse notes 2+ proteinuria on a bedside dipstick. The patient becomes confused and reports visual flickering at the edges of her visual fields. Which of the following is the most appropriate immediate pharmacological intervention?
A) Administer a second dose of methylergonovine 0.2 mg IM to ensure sustained uterine contraction before addressing blood pressure, as uterine atony would worsen the hemodynamic situation
B) Administer magnesium sulfate 6 g IV loading dose as the first-line antihypertensive agent for methylergonovine-induced hypertension because its vasodilatory mechanism directly counteracts ergot-mediated vasoconstriction
C) Administer labetalol 20 mg IV, hydralazine 5–10 mg IV, or nifedipine 10 mg oral immediate-release to treat acute severe hypertension; do not re-administer methylergonovine; obtain urgent neurological assessment for the visual symptoms and confusion given the clinical picture consistent with posterior reversible encephalopathy syndrome
D) Administer nitroprusside IV as the fastest-acting antihypertensive because the severity of this presentation requires the most potent vasodilator available and nitroprusside is the first-line agent for all obstetric hypertensive emergencies
E) Observe the patient for 20 minutes without antihypertensive treatment because acute blood pressure elevations following methylergonovine are self-limited and typically resolve within 15–30 minutes as the drug redistributes from plasma into its large volume of distribution
ANSWER: C
Rationale:
This question asked you to recognize a methylergonovine-induced hypertensive emergency in a patient who was almost certainly pre-eclamptic at the time of drug administration — her admission blood pressure of 132/86 mmHg, proteinuria, and subsequent acute severe hypertension with neurological symptoms (confusion, visual changes) are consistent with a pre-eclamptic vasculature in which methylergonovine's alpha-1 adrenergic and 5-HT2A-mediated vasoconstriction produced a catastrophic blood pressure surge above the already-reduced cerebrovascular autoregulatory ceiling. The correct immediate response is pharmacological treatment of acute severe hypertension (systolic at or above 160 mmHg or diastolic at or above 110 mmHg) with one of the three ACOG-recommended first-line agents: labetalol IV (20 mg initial dose), hydralazine IV (5–10 mg), or nifedipine oral immediate-release (10 mg). Methylergonovine must not be re-administered. The neurological symptoms — confusion and visual flickering — in the context of acute severe hypertension following methylergonovine in a patient with pre-eclampsia features are consistent with early posterior reversible encephalopathy syndrome (PRES), which requires urgent neurological assessment and urgent blood pressure control.
Option A: Option A is incorrect because re-administering methylergonovine in the setting of acute severe hypertension and probable PRES would directly worsen the vasoconstrictive crisis; the uterus has already received the initial dose and the priority is blood pressure control, not additional uterotonic dosing.
Option B: Option B is incorrect because magnesium sulfate is used for seizure prophylaxis in pre-eclampsia, not as a first-line antihypertensive agent; its vasodilatory effect is modest and insufficient to reliably control acute severe hypertension in the timeframe required; labetalol, hydralazine, or nifedipine are the guideline-recommended antihypertensive agents for this presentation.
Option D: Option D is incorrect because nitroprusside IV is reserved for refractory hypertension after first-line agents have failed; it is not the first-line agent for obstetric hypertensive emergencies because its rapid and profound vasodilation is difficult to titrate safely at the bedside, and cyanide toxicity from prolonged infusion is a concern; labetalol, hydralazine, and nifedipine are the first-line choices.
Option E: Option E is incorrect because blood pressure of 182/116 mmHg with neurological symptoms constitutes a hypertensive emergency requiring immediate pharmacological treatment; waiting 20 minutes without intervention in the presence of confusion and visual changes risks intracranial hemorrhage and permanent neurological injury; the redistribution of methylergonovine into its large volume of distribution does not rapidly enough restore blood pressure to safe levels to justify observation alone.
2. A 31-year-old HIV-positive woman on lopinavir boosted with ritonavir delivers vaginally at 38 weeks. Her antepartum blood pressure was consistently 108–118/64–72 mmHg and she has no history of hypertension, coronary disease, or pre-eclampsia. At her postpartum day 4 visit, her uterus is larger than expected and tender, consistent with subinvolution of the placental bed. Her obstetrician considers prescribing oral methylergonovine 0.2 mg four times daily for seven days. Which of the following best describes the correct prescribing decision and its pharmacological basis?
A) Methylergonovine should be avoided in this patient because ritonavir is among the most potent CYP3A4 inhibitors known; co-administration would substantially reduce methylergonovine hepatic clearance, causing progressive drug accumulation with each oral dose over the seven-day course and amplifying both vasoconstrictive and uterotonic effects to an unpredictable and potentially dangerous degree; an alternative uterotonic such as misoprostol or oxytocin that is not metabolized by CYP3A4 should be prescribed instead
B) Methylergonovine can be prescribed safely at half the standard dose (0.1 mg four times daily) because ritonavir's CYP3A4 inhibition reduces clearance by approximately 50%, and halving the dose exactly compensates for the impaired elimination to maintain therapeutic plasma concentrations equivalent to the standard regimen in a patient without this drug interaction
C) Methylergonovine is safe to prescribe in this patient because ritonavir's CYP3A4 inhibitory effect is specific to HIV protease substrates and does not extend to ergot alkaloids, which undergo CYP3A4 hydroxylation through a structurally distinct binding site that ritonavir does not block
D) The interaction between ritonavir and methylergonovine is pharmacodynamic rather than pharmacokinetic; ritonavir independently activates alpha-1 adrenergic receptors as a side effect of its protease inhibitory mechanism, and the concern is additive vasoconstrictive receptor stimulation rather than drug accumulation from impaired metabolism
E) Methylergonovine should be prescribed at the standard dose but the dosing interval should be extended to once daily rather than four times daily; this frequency adjustment is sufficient to prevent clinically meaningful drug accumulation while maintaining adequate average plasma concentrations for uterotonic efficacy over the seven-day course
ANSWER: A
Rationale:
This question asked you to recognize a high-stakes drug interaction that contraindications methylergonovine in a patient who is otherwise an appropriate candidate on cardiovascular grounds. Ritonavir — used here as a pharmacokinetic booster for lopinavir — is one of the most potent CYP3A4 inhibitors in clinical use; this property is deliberately exploited in boosted antiretroviral regimens to elevate co-administered protease inhibitor plasma concentrations, and it applies equally to all CYP3A4 substrates including methylergonovine. Methylergonovine depends on hepatic CYP3A4-mediated hydroxylation to lysergol as its primary elimination pathway; under ritonavir-mediated CYP3A4 inhibition, each oral dose is metabolized far more slowly than normal, producing higher peak plasma concentrations and a substantially prolonged elimination half-life. At standard four-times-daily dosing over seven days, each successive dose accumulates on incompletely cleared residual drug from prior doses, progressively elevating plasma and tissue methylergonovine concentrations well above the intended therapeutic range. The accumulated drug amplifies both vasoconstrictive activity — increasing risk of sustained hypertension and coronary vasospasm — and uterotonic activity beyond the clinically intended level. This interaction is severe enough that methylergonovine is contraindicated with potent CYP3A4 inhibitors; misoprostol (metabolized via de-esterification and beta-oxidation, not CYP3A4) or oxytocin (a peptide degraded by oxytocinase, not CYP enzymes) are safe alternatives for subinvolution management in this patient.
Option B: Option B is incorrect because dose halving does not reliably compensate for ritonavir-mediated CYP3A4 inhibition; the degree of CYP3A4 inhibition by ritonavir is not uniformly 50% and varies depending on the specific substrate, and even a modified dose would still accumulate progressively under potent CYP3A4 inhibition; the appropriate response is avoidance, not dose adjustment.
Option C: Option C is incorrect because ritonavir's CYP3A4 inhibitory activity is not substrate-selective for HIV protease compounds; CYP3A4 is a broad-spectrum enzyme and ritonavir inhibits its activity against all CYP3A4 substrates, including methylergonovine's ergoline structure; there is no structurally distinct CYP3A4 binding site that selectively excludes ergot alkaloids from ritonavir inhibition.
Option D: Option D is incorrect because the clinically relevant interaction between ritonavir and methylergonovine is pharmacokinetic through CYP3A4 inhibition, not pharmacodynamic through direct alpha-1 adrenergic receptor activation; HIV protease inhibitors do not possess intrinsic adrenergic receptor agonism, and the concern is drug accumulation from impaired metabolism rather than receptor-level additivity.
Option E: Option E is incorrect because once-daily dosing does not reliably prevent progressive accumulation when clearance is substantially impaired by a potent CYP3A4 inhibitor; if the elimination half-life has been extended several-fold by ritonavir, once-daily dosing still results in residual drug accumulation from day to day, and the appropriate management is avoidance of the interaction rather than a fixed interval modification.
3. A 34-year-old woman with no history of hypertension undergoes elective cesarean delivery under spinal anesthesia. Immediately after the spinal block is placed her blood pressure drops to 78/48 mmHg and phenylephrine 100 micrograms IV is administered, restoring blood pressure to 122/78 mmHg. The infant is delivered eight minutes later. The obstetrician turns to the anesthesiologist and says, "Let's give methylergonovine now for PPH prophylaxis." The anesthesiologist checks the blood pressure: 116/74 mmHg. The last phenylephrine dose was given six minutes ago. Which of the following most accurately describes the appropriate response from the anesthesiologist?
A) Confirm administration of methylergonovine immediately because the blood pressure is below the 140/90 mmHg contraindication threshold and phenylephrine has no pharmacodynamic interaction with methylergonovine since they act through entirely different receptor systems
B) Recommend delaying methylergonovine until the blood pressure has been pharmacologically lowered to below 100/65 mmHg with additional phenylephrine to create sufficient buffer against the expected vasoconstrictive rise from methylergonovine
C) Recommend replacing methylergonovine with oxytocin 10 IU IM as the PPH prophylaxis agent in all patients who received phenylephrine for spinal-induced hypotension, because phenylephrine permanently sensitizes alpha-1 adrenergic receptors and any subsequent alpha-1 agonist carries a fixed 24-hour period of amplified vasoconstrictive risk
D) Recommend replacing methylergonovine with carboprost as the first-line uterotonic agent because carboprost acts through prostaglandin F receptors and has no pharmacodynamic overlap with phenylephrine, eliminating the interaction risk while providing equivalent uterotonic efficacy
E) Flag that phenylephrine administered six minutes ago may still be pharmacologically active at vascular alpha-1 adrenergic receptors; methylergonovine's own alpha-1 AR and 5-HT2A agonism administered within the same perioperative window could produce additive vasoconstriction and acute severe hypertension; communicate the timing concern to the obstetrician, confirm current blood pressure with continuous monitoring in place, and ensure emergency antihypertensive agents are at the bedside before proceeding
ANSWER: E
Rationale:
This question asked you to apply the pharmacodynamics of the phenylephrine-methylergonovine interaction to a specific intraoperative scenario. Phenylephrine is a selective alpha-1 adrenergic receptor agonist with a plasma half-life of approximately 2–3 minutes after IV bolus; while its peak effect is brief, pharmacologically meaningful alpha-1 AR activation at the vascular level can persist for 10–15 minutes after a 100-microgram IV bolus. At the six-minute mark, phenylephrine may still be contributing residual alpha-1 AR-mediated vasoconstrictive activity. Methylergonovine, when administered in this window, adds its own alpha-1 AR agonism plus 5-HT2A receptor activation to the same vascular smooth muscle, producing additive vasoconstrictive drive that can flip the blood pressure trajectory from the corrected normotension of 116/74 mmHg to acute severe hypertension within minutes — precisely the scenario documented in obstetric anesthesia case series involving this drug combination. The appropriate anesthesiologist response is not to reflexively block methylergonovine administration but to communicate the timing concern clearly, confirm that continuous blood pressure monitoring is established, ensure emergency antihypertensives (labetalol, hydralazine, or nifedipine) are immediately available at the bedside, and proceed with awareness of the interaction risk.
Option A: Option A is incorrect because phenylephrine and methylergonovine do not act through entirely different receptor systems — phenylephrine is a selective alpha-1 AR agonist, and alpha-1 AR activation is one of methylergonovine's two vasoconstrictive mechanisms; the pharmacodynamic overlap at the alpha-1 AR is precisely the basis for the additive interaction risk.
Option B: Option B is incorrect because further lowering blood pressure with additional phenylephrine before methylergonovine is not a logical or guideline-supported approach; adding more of the interacting vasopressor to create hemodynamic "buffer" before the ergot is given does not reduce the interaction risk and would be pharmacologically counterproductive.
Option C: Option C is incorrect because phenylephrine does not permanently sensitize alpha-1 adrenergic receptors or produce a fixed 24-hour period of amplified vasoconstrictive risk; the interaction concern is acute and pharmacokinetically limited to the period during which phenylephrine remains pharmacologically active; after phenylephrine has been eliminated (typically within 15–20 minutes of an IV bolus), the interaction risk resolves.
Option D: Option D is incorrect because carboprost is a third-line uterotonic and is not an appropriate first-line replacement for methylergonovine in routine PPH prophylaxis; furthermore, carboprost carries its own cardiovascular effects including potential hypertension and is absolutely contraindicated in asthma, making it a less universally safe substitute than the option implies.
4. A 29-year-old woman with moderate persistent asthma on fluticasone-salmeterol inhaler delivers vaginally and develops uterine atony. Oxytocin 40 IU in 1 liter of normal saline has been infusing for 30 minutes and methylergonovine 0.2 mg IM was administered 15 minutes ago. The uterus remains poorly contracted. Her blood pressure is 126/80 mmHg. The senior resident presents two options to the attending: "We could give carboprost 250 micrograms IM or misoprostol 800 micrograms rectally as the next step." Which of the following most accurately identifies the correct choice and its mechanistic basis?
A) Carboprost is preferred over misoprostol because its prostaglandin F2-alpha mechanism produces a stronger and more sustained uterotonic contraction than misoprostol's prostaglandin E1 mechanism, and the bronchospasm risk is adequately managed by administering the patient's salmeterol inhaler immediately before the carboprost injection
B) Misoprostol 800 micrograms rectally is the correct choice; carboprost is absolutely contraindicated in this patient because its prostaglandin F2-alpha mechanism activates FP receptors on bronchial smooth muscle, causing bronchoconstriction that can be severe and life-threatening in asthmatic patients and cannot be reliably prevented by bronchodilator pretreatment; misoprostol's prostaglandin E1 mechanism activates EP2 receptors, which are Gs-coupled and produce bronchial smooth muscle relaxation, making it safe in asthma
C) Both carboprost and misoprostol are contraindicated in asthma because all prostaglandin-based agents cause bronchoconstriction through activation of the arachidonic acid cascade; the only remaining pharmacological option in this patient is a second dose of methylergonovine 0.4 mg IM
D) Carboprost 125 micrograms IM at half the standard dose is the correct choice because the bronchoconstriction risk of carboprost is dose-dependent and is eliminated at doses below 200 micrograms; the reduced dose provides adequate uterotonic efficacy while eliminating the pulmonary contraindication in this patient with moderate rather than severe asthma
E) Misoprostol is the less effective choice and should only be used if carboprost is unavailable; the attending should proceed with carboprost at the standard dose and have the anesthesiologist manage any bronchospasm with intubation and bronchodilator therapy as the risk of fatal PPH outweighs the risk of a manageable bronchospastic episode
ANSWER: B
Rationale:
This question asked you to apply the receptor-level distinction between prostaglandin F and E subtypes to a high-stakes clinical decision in an asthmatic patient requiring third-line uterotonic escalation. Carboprost tromethamine is a synthetic prostaglandin F2-alpha (PGF2α) analog that activates FP receptors on bronchial smooth muscle; FP receptors are Gq-coupled and mediate smooth muscle contraction through intracellular calcium mobilization, producing bronchoconstriction. In an asthmatic patient whose bronchial smooth muscle already exhibits heightened reactivity, carboprost-induced FP receptor activation can trigger severe and life-threatening bronchospasm. This is an absolute contraindication that applies regardless of asthma severity, current control status, or inhaled bronchodilator regimen; pretreatment with salmeterol or albuterol does not reliably prevent carboprost-induced bronchospasm in asthmatic patients and is not an endorsed management strategy. Misoprostol is a prostaglandin E1 (PGE1) analog that activates EP2 receptor subtypes among others; EP2 receptors are Gs-coupled, raise intracellular cyclic AMP through adenylyl cyclase activation, and produce bronchial smooth muscle relaxation — the identical signaling pathway activated by beta-2 adrenergic agonists such as salmeterol. Misoprostol therefore does not cause bronchoconstriction and is pharmacologically safe in asthmatic patients, making it the unambiguous correct third-line choice at 800–1,000 micrograms rectally or sublingually.
Option A: Option A is incorrect because asthma is an absolute contraindication to carboprost and this contraindication cannot be managed by pre-administering a long-acting bronchodilator; salmeterol pretreatment does not prevent FP receptor-mediated bronchoconstriction, and the attending should not proceed with carboprost in this patient regardless of bronchodilator availability.
Option C: Option C is incorrect because misoprostol is not contraindicated in asthma; the claim that all prostaglandins cause bronchoconstriction is pharmacologically incorrect — prostaglandin receptor subtype selectivity determines the pulmonary effect, and PGE1 acting at EP2 produces bronchodilation, not bronchoconstriction; misoprostol is a safe and appropriate third-line agent in this patient.
Option D: Option D is incorrect because the absolute contraindication to carboprost in asthma is not dose-dependent in a way that permits safe use at reduced doses; no validated dose threshold below which carboprost is safe in asthmatic patients has been established, and asthma severity classification (moderate versus severe) does not convert the absolute contraindication to a manageable relative one.
Option E: Option E is incorrect because misoprostol is not an inferior fallback to carboprost in all clinical contexts — in an asthmatic patient, misoprostol is the correct and pharmacologically preferred third-line uterotonic, and proceeding with carboprost while planning anesthesia management of bronchospasm is not an appropriate risk-benefit calculation when a safe and effective alternative is available.
5. A community midwife is managing an active third stage of labor at a rural health post in a tropical region. The facility's refrigeration unit failed four weeks ago and has not been repaired. The only uterotonic in the drug cabinet is ergometrine 0.5 mg ampoules stored at ambient temperatures that have ranged from 29 to 36 degrees Celsius over the past four weeks. The patient is a 24-year-old gravida 3 with no hypertension and no contraindications to ergot alkaloids. The midwife also has misoprostol 200 microgram tablets in a sealed foil blister pack stored in a cool dark drawer. Which of the following most accurately guides her uterotonic management decision?
A) Administer the ergometrine ampoule at the standard 0.5 mg IM dose because ergometrine's molecular structure is stable at temperatures up to 40 degrees Celsius and four weeks of ambient tropical storage will not meaningfully reduce its uterotonic potency; the foil-packed misoprostol should be reserved for cases where ergometrine has demonstrably failed
B) Administer both ergometrine 0.5 mg IM and misoprostol 600 micrograms orally simultaneously as combination therapy because the combination provides superior PPH prevention compared with either agent alone, and the potential for reduced ergometrine potency is offset by the full-strength misoprostol component
C) Administer ergometrine at double the standard dose (1.0 mg IM) to compensate for any potency loss from heat exposure; the pharmacokinetic principle of proportional dose-response means that doubling the dose restores effective plasma concentrations even if 50% of drug activity has been lost to thermal degradation
D) Use misoprostol as the uterotonic agent; ergometrine is substantially more heat-labile than misoprostol and requires refrigeration at 2–8 degrees Celsius to maintain potency; four weeks of storage at 29–36 degrees Celsius is sufficient to cause progressive and potentially substantial degradation of the ergometrine ampoule's uterotonic activity, making its efficacy unreliable; misoprostol in sealed foil packaging remains stable at ambient tropical temperatures and is the pharmacologically sound choice for AMTSL in this setting
E) Withhold all uterotonic agents until the patient shows signs of PPH because prophylactic uterotonic administration with a potentially compromised ergometrine supply and a prostaglandin agent not traditionally used in this clinic carries more risk than expectant management of the third stage
ANSWER: D
Rationale:
This question asked you to apply ergometrine's storage requirements and heat-lability profile to a practical clinical scenario where the cold-chain has failed. Ergometrine is substantially more heat-labile than methylergonovine and considerably more heat-labile than misoprostol; it requires refrigerated storage at 2–8 degrees Celsius to maintain potency because its lysergic acid ergoline structure undergoes progressive chemical degradation at ambient temperatures. Four weeks of storage at 29–36 degrees Celsius in a tropical climate constitutes a significant cold-chain failure; the ergometrine ampoule's uterotonic activity is likely substantially compromised, with no reliable way to assess the degree of degradation at the point of care. Using a potentially inactivated ergometrine ampoule for AMTSL in a high-parity patient (gravida 3) at risk for postpartum atony exposes her to inadequate uterotonic coverage without her knowledge. Misoprostol, by contrast, is a synthetic prostaglandin E1 analog formulated as an oral tablet; in sealed foil blister packaging it remains chemically stable at ambient temperatures up to approximately 30 degrees Celsius for up to two years under appropriate storage conditions, making it the pharmacologically sound uterotonic choice when cold-chain storage is unavailable. At 600 micrograms orally or sublingually, misoprostol provides effective AMTSL uterotonic coverage. This is precisely the scenario the WHO foresaw in recommending heat-stable misoprostol as the preferred AMTSL uterotonic in low-resource settings without reliable cold-chain supply.
Option A: Option A is incorrect because ergometrine is not thermally stable at ambient tropical temperatures; its ergoline structure degrades progressively above refrigerated storage temperatures, and four weeks at 29–36 degrees Celsius is sufficient to produce clinically significant potency loss; the claim of stability up to 40 degrees Celsius does not reflect the established heat-lability profile of this compound.
Option B: Option B is incorrect because administering potentially degraded ergometrine alongside misoprostol as combination therapy is not pharmacologically justified; if the ergometrine is substantially inactivated, it contributes no uterotonic benefit and adds unnecessary injection risk; misoprostol alone at the appropriate dose provides effective AMTSL coverage.
Option C: Option C is incorrect because doubling the dose of a potentially heat-degraded ergometrine ampoule does not reliably restore uterotonic efficacy; thermal degradation is a chemical process that produces inactive degradation products, and doubling the administered volume of a degraded solution delivers more degradation products, not more active drug; furthermore, doubling the ergometrine dose amplifies emetic and vasoconstrictive adverse effects if any active drug remains.
Option E: Option E is incorrect because expectant management of the third stage — withholding all prophylactic uterotonics — is associated with substantially higher rates of PPH compared with active management with uterotonic administration; the WHO's AMTSL recommendation is based on evidence that prophylactic uterotonics reduce PPH incidence by approximately 60%; misoprostol is available, stable, and effective, making withholding it inappropriate.
6. A 28-year-old woman is on day 3 of oral clarithromycin 500 mg twice daily, prescribed by her internist for community-acquired pneumonia diagnosed two days postpartum. At her obstetric follow-up visit, the obstetrician independently prescribes oral methylergonovine 0.2 mg four times daily for seven days for uterine subinvolution. The patient fills both prescriptions without either prescriber being aware of the other's order. Her blood pressure is 122/76 mmHg. She has no history of hypertension or coronary disease. On day 3 of the combined regimen she develops a severe headache and her blood pressure in the emergency department is 168/106 mmHg. Which of the following most accurately identifies the mechanism of this presentation and the correct management?
A) Clarithromycin is a potent CYP3A4 inhibitor that has reduced methylergonovine's hepatic clearance, causing progressive accumulation of the parent vasoconstrictive compound over three days of combined use; the elevated plasma methylergonovine concentrations have produced the acute severe hypertension through amplified alpha-1 adrenergic and 5-HT2A receptor-mediated vasoconstriction; clarithromycin should be switched to a non-CYP3A4-inhibiting antibiotic such as doxycycline or azithromycin, methylergonovine should be discontinued, and blood pressure should be treated with labetalol, hydralazine, or nifedipine
B) Clarithromycin has induced CYP3A4 expression, reducing methylergonovine's plasma concentrations below the therapeutic threshold; the hypertension represents a rebound vasoconstrictive response as the uterotonic effect wanes and the uterus involutes abnormally; the correct management is to increase the methylergonovine dose to 0.4 mg four times daily to overcome the induction effect
C) The hypertension is caused by a pharmacodynamic interaction in which clarithromycin independently activates alpha-1 adrenergic receptors through its macrolide lactone ring, adding direct vasoconstrictive activity to methylergonovine's receptor effect; management requires discontinuing both agents simultaneously and administering alpha-1 adrenergic receptor antagonist therapy with prazosin
D) The hypertension reflects postpartum pre-eclampsia that is coincidental to the combined drug regimen; clarithromycin and methylergonovine have no pharmacokinetic interaction, and the blood pressure elevation should be managed as de novo postpartum pre-eclampsia with magnesium sulfate and antihypertensive therapy without any change to the antibiotic regimen
E) The hypertension is caused by clarithromycin-induced inhibition of P-glycoprotein efflux at the blood-brain barrier, increasing methylergonovine central nervous system penetration and triggering a centrally mediated sympathetic hypertensive surge; management requires blood-brain barrier-penetrating antihypertensive therapy with propranolol specifically
ANSWER: A
Rationale:
This question asked you to recognize a clinically dangerous drug interaction arising from concurrent prescribing by two independent providers — a scenario that occurs in real practice when postpartum care is fragmented. Clarithromycin is a potent CYP3A4 inhibitor through mechanism-based (irreversible) inactivation of the CYP3A4 enzyme; its inhibitory effect is sustained and cumulative, reaching maximal inhibitory intensity within 2–3 days of regular dosing. Methylergonovine depends on hepatic CYP3A4 hydroxylation as its primary elimination pathway. Under clarithromycin-mediated CYP3A4 inhibition, each four-times-daily dose of methylergonovine undergoes progressively impaired clearance, and by day 3 of the combined regimen, plasma and tissue methylergonovine concentrations have accumulated substantially above the intended therapeutic range. The elevated drug concentrations amplify alpha-1 adrenergic and 5-HT2A receptor-mediated vasoconstriction throughout the systemic and coronary vasculature, producing the acute severe hypertension presenting in the emergency department. Correct management requires: discontinuing methylergonovine (the vasoconstrictive agent whose accumulation is causing the crisis); switching clarithromycin to an antibiotic that does not inhibit CYP3A4 — doxycycline and azithromycin are appropriate alternatives for community-acquired pneumonia that do not share clarithromycin's CYP3A4 inhibitory profile; and treating the acute severe hypertension with one of the guideline-recommended antihypertensive agents (labetalol IV, hydralazine IV, or nifedipine oral immediate-release).
Option B: Option B is incorrect because clarithromycin is a CYP3A4 inhibitor, not an inducer; CYP3A4 induction (which would reduce substrate concentrations) is produced by drugs such as rifampin, carbamazepine, and St. John's wort — clarithromycin has the opposite effect, increasing rather than decreasing methylergonovine plasma concentrations.
Option C: Option C is incorrect because clarithromycin does not directly activate alpha-1 adrenergic receptors through its macrolide structure; macrolide antibiotics do not possess intrinsic adrenergic receptor pharmacology, and the interaction is pharmacokinetic through CYP3A4 inhibition, not pharmacodynamic through receptor agonism; prazosin as management reflects a mischaracterization of the interaction mechanism.
Option D: Option D is incorrect because while postpartum pre-eclampsia is a real clinical entity, dismissing the drug interaction as coincidental in a patient taking two agents with a well-characterized and severe CYP3A4-based pharmacokinetic interaction that produces hypertension is clinically inappropriate; the temporal relationship — hypertension emerging on day 3 of combined clarithromycin and methylergonovine use — is consistent with the expected kinetics of CYP3A4 inhibitor-mediated drug accumulation.
Option E: Option E is incorrect because P-glycoprotein inhibition at the blood-brain barrier is not the established mechanism of the clarithromycin-methylergonovine interaction; the interaction is hepatic CYP3A4 inhibition producing systemic drug accumulation, not increased central nervous system drug penetration; propranolol is not specifically indicated for centrally mediated sympathetic hypertension from this interaction.
7. A 36-year-old woman with a known history of Prinzmetal angina (coronary artery vasospasm), well controlled on diltiazem 180 mg daily, delivers vaginally after an uncomplicated labor. She has no hypertension and her blood pressure is 114/70 mmHg throughout labor and delivery. Immediately after placental delivery she develops uterine atony. Standard oxytocin 40 IU in 1 liter of normal saline is initiated and bimanual uterine massage performed, but the uterus remains poorly contracted after 20 minutes and active bleeding continues. The resident asks the attending, "Should we give methylergonovine now?" Which of the following most accurately describes the correct uterotonic management decision?
A) Administer methylergonovine 0.2 mg IM because Prinzmetal angina is a relative rather than absolute contraindication when given by the intramuscular route; the gradual absorption profile provides adequate time to monitor for coronary vasospasm and administer sublingual nitroglycerin if needed
B) Administer methylergonovine 0.2 mg IM at half the standard dose (0.1 mg) because the reduced dose produces adequate uterotonic receptor activation without achieving the threshold plasma concentration required for coronary artery vasospasm in a patient already on diltiazem calcium channel blockade
C) Methylergonovine is absolutely contraindicated in this patient because its alpha-1 adrenergic and 5-HT2A receptor agonism causes coronary artery vasoconstriction that is not selective for the uterine vasculature; in a patient with established coronary vasospasm, ergot-mediated coronary vasoconstriction carries substantial risk of acute myocardial infarction; escalate to carboprost 250 micrograms IM if no asthma history, or misoprostol 800–1,000 micrograms rectally if carboprost is contraindicated, while continuing oxytocin
D) Administer methylergonovine because diltiazem, as a calcium channel blocker, will prevent the coronary arterial smooth muscle calcium influx required for methylergonovine-induced vasospasm, effectively neutralizing the coronary vasospasm risk while allowing full uterotonic receptor activation in the myometrium
E) Defer all further uterotonic escalation and proceed directly to uterine compression sutures because Prinzmetal angina is a contraindication to all available uterotonic agents including oxytocin, carboprost, and misoprostol, making surgical management the only safe option in this patient
ANSWER: C
Rationale:
This question asked you to apply the absolute cardiovascular contraindication profile of methylergonovine to a patient in whom the indication for escalation is clear but the contraindication is equally clear. Coronary artery disease and coronary artery vasospasm — including Prinzmetal angina, which is defined by episodic coronary smooth muscle spasm — are absolute contraindications to methylergonovine. Methylergonovine's vasoconstrictive mechanism operates through alpha-1 adrenergic receptor and 5-HT2A receptor agonism on vascular smooth muscle; these receptors are expressed not only in the uterine vasculature but throughout the systemic and coronary circulation, and methylergonovine-induced coronary vasoconstriction is a well-documented cause of acute myocardial infarction. In a patient with established Prinzmetal angina — a condition defined by pathological coronary vasoreactivity — the pharmacological induction of additional coronary vasoconstrictive tone carries substantial risk of precipitating acute coronary occlusion and myocardial infarction. The answer to the resident's question is therefore an unambiguous no to methylergonovine, with escalation proceeding to carboprost 250 micrograms IM (if no asthma contraindication) or misoprostol 800–1,000 micrograms rectally (if carboprost is contraindicated), while maintaining the oxytocin infusion.
Option A: Option A is incorrect because coronary artery vasospasm is an absolute, not relative, contraindication to methylergonovine; the intramuscular route does not eliminate the coronary vasoconstrictive risk — documented cases of acute myocardial infarction following methylergonovine involve intramuscular administration — and sublingual nitroglycerin is a reactive rather than preventive management approach that is not an endorsed strategy for enabling methylergonovine use in this patient population.
Option B: Option B is incorrect because the coronary vasospasm contraindication is absolute and does not permit dose reduction as a risk mitigation strategy; no dose threshold below which methylergonovine is safe in patients with established coronary vasospasm has been validated, and diltiazem pretreatment does not reliably prevent ergot-induced coronary vasoconstriction.
Option D: Option D is incorrect because diltiazem blocks L-type voltage-gated calcium channels and reduces calcium influx during membrane depolarization in vascular smooth muscle, but it does not block receptor-operated calcium channels activated by Gq-coupled alpha-1 AR and 5-HT2A receptor signaling; methylergonovine-induced coronary vasoconstriction proceeds through IP3-mediated intracellular calcium release from the sarcoplasmic reticulum rather than exclusively through L-type channel calcium influx, meaning diltiazem does not fully protect against ergot-mediated coronary vasospasm.
Option E: Option E is incorrect because the contraindication to methylergonovine does not extend to all available uterotonic agents; oxytocin (already running), carboprost (no asthma contraindication stated), and misoprostol are all options without the coronary vasospasm contraindication, and surgical escalation is premature before exhausting pharmacological options.
8. A 33-year-old woman with Child-Pugh class B hepatic cirrhosis from chronic hepatitis C, currently managed with direct-acting antivirals, delivers vaginally at 37 weeks. Her blood pressure is consistently 106–116/64–72 mmHg. At her postpartum day 5 visit the uterus is larger and softer than expected for day 5, and she has heavier-than-expected lochia. The obstetrician diagnoses uterine subinvolution and considers pharmacological management. Which of the following most accurately guides the uterotonic prescribing decision for this patient?
A) Prescribe oral methylergonovine 0.2 mg four times daily at the standard dose and interval because hepatic cirrhosis does not impair CYP3A4-mediated methylergonovine metabolism; CYP3A4 is a microsomal enzyme constitutively expressed at consistent levels regardless of hepatic fibrosis or portal hypertension, making cirrhosis pharmacokinetically irrelevant for this drug
B) Prescribe misoprostol or arrange low-dose oxytocin as the alternative uterotonic; Child-Pugh class B cirrhosis substantially reduces hepatic CYP3A4 activity, impairing methylergonovine clearance and prolonging its elimination half-life; at standard four-times-daily dosing over the extended postpartum course, progressive drug accumulation would amplify both vasoconstrictive and uterotonic effects beyond the intended therapeutic range; methylergonovine should be avoided in favor of agents not dependent on hepatic CYP3A4 for elimination
C) Prescribe oral methylergonovine 0.2 mg once daily instead of four times daily; this frequency reduction exactly compensates for the impaired CYP3A4-mediated clearance in Child-Pugh B cirrhosis while maintaining therapeutic average plasma concentrations, and is the established dose-modification protocol for this indication in patients with hepatic impairment
D) Prescribe oral methylergonovine at the standard dose and interval but add a proton pump inhibitor to reduce gastrointestinal adverse effects from the combination of cirrhosis-related gastric dysmotility and oral ergot alkaloid administration; no pharmacokinetic dose adjustment is required because methylergonovine's large volume of distribution buffers plasma concentration changes from impaired hepatic clearance
E) Prescribe oral methylergonovine 0.4 mg twice daily in place of 0.2 mg four times daily; reducing the dosing frequency while doubling the individual dose maintains the same total daily dose and reduces the number of daily CYP3A4 metabolic events required, thereby lowering the cumulative clearance demand on the impaired hepatic enzyme system
ANSWER: B
Rationale:
This question asked you to apply methylergonovine's elimination pharmacology to a clinical scenario involving significant hepatic impairment. Methylergonovine's primary elimination pathway is CYP3A4-mediated hepatic hydroxylation to lysergol, with biliary-fecal excretion as the predominant route of drug and metabolite removal. Child-Pugh class B cirrhosis reflects substantial hepatocellular dysfunction: reduced functional hepatocyte mass, impaired hepatic blood flow through the diseased parenchyma, and decreased expression and catalytic activity of CYP450 enzymes including CYP3A4. Under these conditions, methylergonovine clearance is substantially reduced and the elimination half-life is prolonged well beyond the normal 2–3.5 hours. At standard four-times-daily dosing over an extended postpartum course, each successive dose is administered before the preceding dose has been adequately eliminated; plasma and tissue concentrations rise progressively with each dose, accumulating to levels that amplify vasoconstrictive effects — including risk of sustained hypertension and coronary vasospasm — beyond the intended therapeutic range. The pharmacokinetically sound management is to avoid methylergonovine and use agents whose elimination does not depend on hepatic CYP3A4: misoprostol is metabolized by de-esterification and beta-oxidation pathways not substantially impaired in Child-Pugh B cirrhosis; oxytocin is a peptide hormone degraded by oxytocinase rather than CYP enzymes.
Option A: Option A is incorrect because Child-Pugh class B cirrhosis does substantially impair CYP3A4 expression and activity; hepatic fibrosis, loss of functional hepatocyte mass, and impaired portal flow all reduce the capacity for CYP450-mediated drug metabolism; the claim that CYP3A4 is constitutively expressed at consistent levels regardless of cirrhosis severity is pharmacologically incorrect and has been contradicted by clinical pharmacokinetic studies in cirrhotic patients.
Option C: Option C is incorrect because once-daily dosing does not reliably prevent progressive accumulation when CYP3A4 clearance is substantially impaired; the degree of CYP3A4 reduction in Child-Pugh B cirrhosis is not uniformly predictable, and a fixed once-daily adjustment does not ensure safe plasma concentrations across the full range of patients in this Child-Pugh class; avoidance is pharmacologically superior to dose-interval adjustment.
Option D: Option D is incorrect because the large volume of distribution does not buffer plasma concentration changes from impaired hepatic clearance; Vd governs the distribution of drug between plasma and peripheral tissues at any given plasma concentration, but when clearance is reduced, each dose produces a higher plasma peak and slower decline regardless of Vd; adding a proton pump inhibitor does not address the pharmacokinetic accumulation risk.
Option E: Option E is incorrect because reducing dosing frequency while doubling the individual dose maintains the same total daily dose under impaired clearance — it does not reduce the accumulation problem; if the half-life has been doubled by cirrhosis, twice-daily dosing of a double dose produces the same accumulation pattern as four-times-daily dosing of a standard dose over the same total daily drug exposure; the approach does not reduce the pharmacokinetic risk of impaired clearance.
9. A 30-year-old woman with pre-eclampsia (blood pressure 146/94 mmHg on admission, proteinuria 2+) delivers vaginally after magnesium sulfate seizure prophylaxis. In the immediate postpartum period, a covering resident who is unaware of her pre-eclampsia diagnosis administers methylergonovine 0.2 mg IM for routine PPH prophylaxis. Eight minutes later the patient reports a severe occipital headache. Her blood pressure is 178/116 mmHg. She develops confusion and loses vision in both temporal fields. The attending is called immediately. Recognizing this as methylergonovine-induced hypertensive emergency with features consistent with posterior reversible encephalopathy syndrome (PRES), which of the following represents the single most important action the team must NOT take in the immediate management of this patient?
A) Administer labetalol 20 mg IV to initiate antihypertensive treatment for the acute severe hypertension
B) Obtain urgent neuroimaging (MRI or CT) to evaluate for intracranial hemorrhage or posterior white matter edema
C) Continue magnesium sulfate infusion for ongoing seizure prophylaxis given the high risk of eclampsia in the context of acute severe hypertension
D) Administer nifedipine 10 mg oral immediate-release as an alternative first-line antihypertensive if IV access is delayed
E) Administer a second dose of methylergonovine 0.2 mg IM to ensure adequate uterine tone is maintained during the blood pressure crisis, reasoning that uterine atony would compound the hemodynamic instability
ANSWER: E
Rationale:
This question asked you to identify the single most dangerous error in a rapidly evolving methylergonovine-induced hypertensive emergency with features of PRES. The patient is experiencing acute severe hypertension (blood pressure 178/116 mmHg), confusion, and bilateral temporal visual field deficits following methylergonovine administration in the context of pre-eclampsia — a clinical presentation consistent with the early stages of PRES, driven by failure of cerebrovascular autoregulation after methylergonovine's vasoconstrictive mechanism pushed mean arterial pressure above the already-reduced autoregulatory ceiling of the pre-eclamptic vasculature. In this setting, the single action the team must unequivocally not take is administering a second dose of methylergonovine. Re-administration of the causative vasoconstrictive agent in the middle of a hypertensive emergency that it has precipitated would directly and immediately worsen the vasoconstrictive crisis, further raising blood pressure, increasing the risk of intracranial hemorrhage, and potentially extending or irreversibly establishing the PRES edema that is already developing. Methylergonovine is absolutely contraindicated from this moment forward in this patient's management. All other listed options are appropriate: labetalol IV and nifedipine oral immediate-release are first-line antihypertensive agents for this presentation; urgent neuroimaging is appropriate to evaluate for hemorrhagic transformation or evolving edema; and continuing magnesium sulfate is appropriate for ongoing seizure prophylaxis in a patient with acute severe hypertension and probable PRES in the context of pre-eclampsia.
Option A: Option A is incorrect as a choice because labetalol 20 mg IV is appropriate management — it is a first-line ACOG-recommended antihypertensive for acute severe hypertension in obstetric patients and should be administered promptly in this scenario.
Option B: Option B is incorrect as a choice because urgent neuroimaging is appropriate and clinically necessary given the neurological symptoms; bilateral visual field deficits and confusion in the context of acute severe hypertension warrant imaging to evaluate for intracranial hemorrhage or PRES edema.
Option C: Option C is incorrect as a choice because continuing magnesium sulfate is appropriate; this patient is at high risk of eclamptic seizure given her pre-eclampsia diagnosis and the superimposed acute severe hypertension with neurological involvement.
Option D: Option D is incorrect as a choice because nifedipine oral immediate-release is an appropriate first-line antihypertensive alternative when IV access is not immediately available and is guideline-endorsed for this indication.
10. A 22-year-old primigravida at 40 weeks gestation is in active labor with cervical dilation progressing slowly. Uterine contractions are occurring every 6–8 minutes, last 35–40 seconds, and are of mild intensity on palpation. The fetal heart rate tracing is category I. A labor and delivery nurse mentions to the midwife that methylergonovine is available in the medication drawer and suggests it might augment uterine contractility. Which of the following most accurately explains why methylergonovine cannot be used for labor augmentation, and identifies the appropriate agent?
A) Methylergonovine cannot be used for labor augmentation because it is only effective in the postpartum uterus; its alpha-1 adrenergic and 5-HT2A receptors are not expressed in the antepartum myometrium, making it pharmacologically inert during active labor regardless of the dose administered
B) Methylergonovine cannot be used because it requires an intact placenta to generate the active receptor-binding metabolite that produces myometrial contraction; in the antepartum period before placental delivery, the drug is metabolized to an inactive compound by placental enzymes before reaching uterine smooth muscle
C) Methylergonovine cannot be used for labor augmentation because it is a prostaglandin synthesis inhibitor that reduces uterine contractility rather than increasing it; in the antepartum uterus, prostaglandin E2 is the primary driver of cervical ripening and myometrial activation, and methylergonovine's inhibitory effect would worsen rather than improve contraction frequency
D) Methylergonovine cannot be used for labor augmentation because it produces sustained tonic myometrial contraction with minimal relaxation intervals; while tonic contraction is hemostatic and appropriate for the postpartum period, intrapartum tonic contraction eliminates the perfusion intervals between contractions that replenish the intervillous space with oxygenated maternal blood, causing fetal hypoxia; the appropriate agent for labor augmentation is oxytocin, which produces rhythmic phasic contractions with adequate relaxation phases that preserve uteroplacental blood flow
E) Methylergonovine cannot be used for labor augmentation because it causes premature placental separation by constricting the spiral arteries at the placental implantation site through its alpha-1 adrenergic mechanism, precipitating placental abruption in women who are administered the drug before placental delivery
ANSWER: D
Rationale:
This question asked you to apply the pharmacodynamic distinction between tonic and phasic uterine contraction — and its physiological consequence for uteroplacental blood flow — to a clinical scenario where the temptation to use an available uterotonic agent is pharmacologically incorrect. Methylergonovine produces sustained tonic myometrial contraction through alpha-1 adrenergic and 5-HT2A receptor activation; both receptor subtypes are Gq-coupled and drive sustained intracellular calcium mobilization, producing persistently elevated myometrial tone with minimal relaxation intervals. This tonic contraction pattern is precisely what makes methylergonovine effective for postpartum hemostasis: persistent mechanical compression of uterine sinusoids closes the spiral arteries at the placental bed, reducing blood loss. However, in the intrapartum setting, sustained tonic contraction without relaxation phases eliminates the intervals between contractions during which the myometrium relaxes, uterine blood flow is restored, and the intervillous space is replenished with oxygenated maternal blood. Continuous tonic contraction — equivalent to a tetanic contraction or uterine hyperstimulation — compresses the intervillous space persistently, cutting off fetal oxygen supply and rapidly producing fetal hypoxia, acidosis, and potential demise. Labor augmentation requires phasic contractions — rhythmic peaks of contractile activity followed by adequate relaxation intervals — which is precisely the pattern produced by oxytocin through Gq-coupled oxytocin receptors; oxytocin-driven contractions mimic the physiological labor contraction pattern and are safe for the fetus when appropriately monitored.
Option A: Option A is incorrect because alpha-1 adrenergic and 5-HT2A receptors are expressed in the antepartum myometrium; the restriction on intrapartum methylergonovine use is pharmacodynamic (tonic contraction pattern), not a consequence of absent receptor expression; methylergonovine would produce myometrial contraction in the antepartum uterus — which is exactly why it is dangerous, not because it fails to act.
Option B: Option B is incorrect because methylergonovine is not converted to an active metabolite by the placenta; the parent compound is the pharmacologically active agent and it crosses the placenta and reaches myometrial tissue in the antepartum period; placental inactivation is not the basis for its restricted use in labor.
Option C: Option C is incorrect because methylergonovine is not a prostaglandin synthesis inhibitor; it has no meaningful cyclooxygenase inhibitory activity and does not reduce prostaglandin E2 production; its mechanism is direct alpha-1 AR and 5-HT2A receptor agonism on myometrial smooth muscle.
Option E: Option E is incorrect because methylergonovine does not cause premature placental separation through spiral artery constriction; the mechanism of placental abruption involves disruption of the decidual-placental interface, and while ergot alkaloids do constrict spiral arteries in the vasculature, the clinical risk of intrapartum methylergonovine is fetal hypoxia from tonic contraction, not placental abruption from vascular constriction.
11. A 25-year-old woman delivers vaginally. Immediately after placental delivery, her blood pressure is 124/80 mmHg and methylergonovine 0.2 mg IM is administered for PPH prophylaxis. Six minutes later her blood pressure is 192/120 mmHg — a rise far exceeding what is expected from methylergonovine alone in a normotensive patient. She is agitated and reports chest tightness. A urine toxicology screen ordered for unrelated reasons returns positive for cocaine. The attending asks the pharmacology-trained resident: "What receptor mechanism most directly explains why this patient's response to methylergonovine was so much more severe than expected?" Which of the following most accurately answers the attending's question?
A) Cocaine inhibits neuronal reuptake of norepinephrine and serotonin, increasing synaptic concentrations of both neurotransmitters at vascular alpha-1 adrenergic and 5-HT2A receptors; this elevated endogenous agonist tone at the same receptor targets that methylergonovine directly activates produces additive vasoconstrictive drive — cocaine-sensitized alpha-1 AR and 5-HT2A receptor systems respond to methylergonovine's partial agonism with a vasoconstrictive response magnitudes greater than methylergonovine alone would produce at a receptor baseline unperturbed by elevated endogenous neurotransmitters
B) Cocaine directly activates dopamine D2 receptors in the central vasomotor center of the medulla, producing a centrally mediated sympathetic surge that amplifies the peripheral vasoconstrictive effect of methylergonovine through a central rather than peripheral receptor mechanism; the severity of the response reflects the combined central and peripheral contributions
C) Cocaine inhibits CYP3A4 in the liver, substantially reducing methylergonovine clearance after intramuscular absorption and producing plasma drug concentrations threefold to fourfold above expected levels within six minutes; the elevated drug concentrations then drive proportionally greater alpha-1 AR and 5-HT2A receptor activation through simple mass-action pharmacokinetics
D) Cocaine irreversibly inactivates endothelial nitric oxide synthase (eNOS) through covalent modification of the enzyme's active site, eliminating the endothelium-derived vasodilatory tone that normally buffers methylergonovine's vasoconstrictive receptor effects; the loss of nitric oxide counterbalance unmasks the full vasoconstrictive potential of alpha-1 AR and 5-HT2A activation by methylergonovine
E) Cocaine upregulates alpha-1 adrenergic receptor gene expression in vascular smooth muscle over the 24–48 hours preceding delivery, substantially increasing receptor density; methylergonovine then encounters a vascular smooth muscle receptor pool of two to three times the normal density, producing proportionally amplified vasoconstriction through increased receptor occupancy at standard drug concentrations
ANSWER: A
Rationale:
This question asked you to precisely identify the receptor-level mechanism of the cocaine-methylergonovine interaction — not merely that an interaction exists, but which specific receptor pharmacology explains its severity. Cocaine's primary mechanism relevant to this interaction is neuronal reuptake inhibition of norepinephrine and serotonin: cocaine blocks the norepinephrine transporter (NET) and the serotonin transporter (SERT) at presynaptic nerve terminals in sympathetic neuroeffector junctions, preventing clearance of released neurotransmitters from the synapse and thereby increasing the concentration of both norepinephrine and serotonin at postsynaptic receptors. At vascular smooth muscle, elevated synaptic norepinephrine activates alpha-1 adrenergic receptors — the same receptor target as methylergonovine — producing sustained Gq-coupled vasoconstriction and receptor sensitization; elevated synaptic serotonin activates 5-HT2A receptors — also the same receptor target as methylergonovine — adding further vasoconstrictive tone through the same intracellular calcium pathway. When methylergonovine is then administered, it acts as a direct partial agonist at both receptor systems that cocaine has already sensitized with elevated endogenous agonist tone; the combined receptor activation — elevated endogenous neurotransmitters plus direct methylergonovine agonism at the identical receptor targets — produces an additive and potentially synergistic vasoconstrictive response that far exceeds what methylergonovine would produce at receptor systems in their unstimulated baseline state. This specific receptor-overlap mechanism is the direct answer to the attending's question.
Option B: Option B is incorrect because cocaine's central vasomotor effects are not the primary mechanism of the peripheral vascular interaction with methylergonovine; while cocaine does produce central stimulant effects through dopaminergic mechanisms, the peripheral vasoconstrictive synergy with methylergonovine operates through peripheral vascular alpha-1 AR and 5-HT2A receptor co-activation from elevated synaptic neurotransmitter concentrations, not through central dopaminergic sympathetic amplification.
Option C: Option C is incorrect because cocaine does not inhibit hepatic CYP3A4 in a clinically meaningful way; cocaine is metabolized by plasma cholinesterases and hepatic esterases through non-CYP pathways, and does not alter CYP3A4 activity; furthermore, meaningful CYP3A4-mediated accumulation cannot produce a threefold to fourfold plasma concentration elevation within six minutes of intramuscular methylergonovine administration, as absorption from the IM site is still ongoing and peak plasma concentrations are not reached until 20–30 minutes.
Option D: Option D is incorrect because cocaine does not irreversibly inactivate eNOS through covalent modification; while cocaine does impair endothelial function and reduce nitric oxide bioavailability through indirect mechanisms including oxidative stress and endothelial damage from chronic use, the acute interaction with methylergonovine in this scenario is receptor-mediated through neurotransmitter reuptake inhibition, not through permanent enzymatic inactivation of eNOS.
Option E: Option E is incorrect because receptor upregulation through gene expression changes requires hours to days of sustained receptor signaling and is a mechanism of chronic adaptation rather than acute pharmacodynamic sensitization; the relevant cocaine mechanism in this acute clinical scenario is elevated synaptic neurotransmitter concentrations from reuptake inhibition occurring in real-time, not transcriptional upregulation of receptor density from prior exposure.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.